Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Cash from Operations: 2021-2025

Historic Cash from Operations for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to -$47.0 million.

  • ARS Pharmaceuticals' Cash from Operations fell 225.20% to -$47.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$85.4 million, marking a year-over-year decrease of 86.16%. This contributed to the annual value of $13.5 million for FY2024, which is 122.86% up from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Cash from Operations is -$47.0 million, which was down 18.83% from -$39.6 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Cash from Operations registered a high of $42.0 million during Q4 2024, and its lowest value of -$47.0 million during Q3 2025.
  • For the 3-year period, ARS Pharmaceuticals' Cash from Operations averaged around -$15.7 million, with its median value being -$14.5 million (2024).
  • Its Cash from Operations has fluctuated over the past 5 years, first spiked by 341.33% in 2024, then tumbled by 507.18% in 2025.
  • ARS Pharmaceuticals' Cash from Operations (Quarterly) stood at $27.9 million in 2021, then plummeted by 173.48% to -$20.5 million in 2022, then grew by 15.09% to -$17.4 million in 2023, then soared by 341.33% to $42.0 million in 2024, then plummeted by 225.20% to -$47.0 million in 2025.
  • Its Cash from Operations was -$47.0 million in Q3 2025, compared to -$39.6 million in Q2 2025 and -$40.7 million in Q1 2025.